Edition:
United States

AzurRx BioPharma Inc (AZRX.OQ)

AZRX.OQ on NASDAQ Stock Exchange Capital Market

2.91USD
13 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.91
Open
$2.96
Day's High
$2.96
Day's Low
$2.96
Volume
33
Avg. Vol
13,057
52-wk High
$5.25
52-wk Low
$2.40

Chart for

About

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.... (more)

Overall

Beta: --
Market Cap(Mil.): $33.62
Shares Outstanding(Mil.): 11.55
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.07 15.47
EPS (TTM): -- -- --
ROI: -- 15.07 33.71
ROE: -- 16.57 16.38

BRIEF-AzurRx Biopharma files for mixed shelf offering of up to $10 mln

* AzurRx Biopharma Inc files for mixed shelf offering of up to $10 million - SEC filing‍​ Source text: [http://bit.ly/2z4AEuv] Further company coverage:

Nov 01 2017

BRIEF-Azurrx Biopharma, Mayoly Spindler announce IMPD submission

* Azurrx Biopharma and Mayoly Spindler announce MS1819-SD investigational medicinal product dossier (IMPD) submission

Oct 20 2017

BRIEF-AzurRx BioPharma files for stock shelf of upto $10 mln

* Azurrx biopharma inc files for stock shelf of upto $10 million - sec filing‍​‍​ Source text for Eikon: (http://bit.ly/2hChpOb) Further company coverage:

Oct 11 2017

BRIEF-AzurRx Biopharma announces positive MS1819-SD Phase II data in exocrine pancreatic insufficiency

* AzurRx Biopharma and Mayoly-Spindler announce positive MS1819-SD phase II data in exocrine pancreatic insufficiency (epi)

Sep 27 2017

BRIEF-Azurrx announces appointment of Chief Financial Officer

* Azurrx announces appointment of Maged Shenouda as Chief Financial Officer Source text for Eikon: Further company coverage:

Sep 25 2017

BRIEF-Azurrx reaches 6th patient enrollment of midstage trial for pancreas drug

* Azurrx reaches 6th patient enrollment of Phase IIA trial of MS1819 for treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis

Aug 23 2017

BRIEF-Azurrx Biopharma enters into sublicense agreement with Transchem

* Azurrx Biopharma Inc - ‍on August 7, 2017, Azurrx Biopharma, Inc entered into a sublicense agreement with Transchem, Inc. - sec filing​

Aug 11 2017

BRIEF-Azurrx Biopharma Inc files for offering of 5.9 million shares of common stock

* Azurrx Biopharma Inc files for offering of 5.9 million shares of common stock by the selling stockholders Source text: (http://bit.ly/2uhef9X) Further company coverage:

Jul 21 2017

Earnings vs. Estimates